Medical Condition News

RSS

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

6 Jun 2012

Patients with type 2 diabetes have 20% increased risk of blood cancers

Patients with type 2 diabetes have a 20 percent increased risk of developing blood cancers, such as non-Hodgkin lymphoma, leukemia and myeloma, according to a new meta-analysis led by researchers at The Miriam Hospital.

6 Jun 2012

FDA issues complete response letter to Merck’s ridaforolimus NDA

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for ridaforolimus.

6 Jun 2012

bioTheranostics’ CancerTYPE ID molecular test improves overall survival for patients with CUP

bioTheranostics, developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced study results showing that tumor profiling with its CancerTYPE ID molecular test helped guide site-specific chemotherapy and improve overall survival for patients with carcinoma of unknown primary site.

6 Jun 2012

UCSF's ACT program helps amputees reach their athletic goals

Carlos Gonzalez stands out from an athletic group gathered on a grassy field at the UCSF Mission Bay campus. The gregarious 32-year-old sports a stylish fauxhawk and walks with a confident yet understated swagger. He's training to become a mixed martial arts (MMA) fighter.

6 Jun 2012

Inflammation instigated by the immune system in ALS can trigger macrophages

In an early study, UCLA researchers found that the immune cells of patients with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, may play a role in damaging the neurons in the spinal cord.

6 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for the Company's oral anticancer compound, perifosine, in multiple myeloma, have been published in the online May 2012 issue of the British Journal of Haematology.

6 Jun 2012

Firefly surgical technology sheds new light on kidney cancers

A surgical technology called Firefly is shedding new light on kidney cancers and helping doctors at MedStar Georgetown University Hospital remove tumors more safely and more efficiently while sparing the rest of the healthy kidney.

6 Jun 2012

BioLineRx receives two U.S. patent allowances for BL-1021 to treat neuropathic pain

BioLineRx, a biopharmaceutical development company, announced today that two Notices of Allowance have been issued by the United States Patent and Trademark Office (USPTO) for BL-1021, an orally available small molecule for treating neuropathic pain.

6 Jun 2012

NTNU’s EIR software to be showcased at 7th World Research Congress of the EAPC

What happens when doctors cannot cure a disease? What is the best way to make patients comfortable and have the best quality of life possible in the time they have left? Researchers at the Norwegian University of Science and Technology (NTNU) have developed software that can be used with an iPad or other tablet to help record patient pain levels to help doctors in developing further treatment.

6 Jun 2012

VGXI, OncoSec partner to produce interleukin-12 plasmid DNA

OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced today that the Company has entered into an exclusive cGMP manufacturing agreement with VGXI Inc. (VGXI) for the production of interleukin-12 plasmid DNA.

6 Jun 2012

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

ThromboGenics NV and co-development partner BioInvent International announce today that they will regain global rights to TB-403 from Roche.

6 Jun 2012

Special echocardiograms show promise for early detection of heart disease in RA patients

Special echocardiograms show promise for early detection of a potentially deadly complication in rheumatoid arthritis: heart disease, Mayo Clinic research shows. The findings were being presented at The European League Against Rheumatism annual meeting in Berlin.

6 Jun 2012

UCSD researchers receive $4M NIMH grant to study accelerated biological aging in schizophrenia

Researchers at the Stein Institute for Research on Aging at the University of California, San Diego have received a $4 million grant from the National Institute of Mental Health (NIMH), part of the National Institutes of Health, to study accelerated biological aging in schizophrenia.

6 Jun 2012

Transgenomic introduces ICE COLD-PCR mutation detection technology

Transgenomic, Inc. today announced the commercial launch of its ICE COLD-PCR mutation detection technology, a breakthrough technology enabling unmatched sensitivity and complete DNA mutation detection using the standard sequencing equipment already installed in laboratories around the world.

6 Jun 2012

SANUWAVE’s ESWT stimulates proliferation of cambium cells for bone generation

SANUWAVE Health, Inc., today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Company's Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone.

6 Jun 2012

Study identifies existence of an antitumor molecule that originates within SMYD3 oncogene

A common point in all human tumors is that they produce an activation of oncogenes, genes that cause cancer and they also cause a loss of function of the protective genes, called anti-oncogenes or tumour suppressor genes. Normally both categories of anticancer and procancer genes are in different regions of our chromosomes.

6 Jun 2012

High pollution increases risk of repeated heart attacks by over 40%

Air pollution, a serious danger to the environment, is also a major health risk, associated with respiratory infections, lung cancer and heart disease. Now a Tel Aviv University researcher has concluded that not only does air pollution impact cardiac events such as heart attack and stroke, but it also causes repeated episodes over the long term.

6 Jun 2012

Nicotinamide riboside can protect against obesity

A natural ingredient found in milk can protect against obesity even as mice continue to enjoy diets that are high in fat. The researchers who report their findings in the June Cell Metabolism, a Cell Press publication, liken this milk ingredient to a new kind of vitamin.

6 Jun 2012

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.

6 Jun 2012